Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Ireland expects to decide on AstraZeneca rollout on Friday

Thu, 18th Mar 2021 18:04

DUBLIN, March 18 (Reuters) - Ireland expects to announce on
Friday its decision on whether to resume the roll-out of the
AstraZeneca COVID-19 vaccine, Deputy Chief Medical
Officer Ronan Glynn told journalists.

Ireland temporarily suspended the AstraZeneca vaccine on
Sunday "out of an abundance of caution" after reports of blood
clotting.

The EU's drug watchdog said on Thursday it is still
convinced the benefits of the vaccine outweigh the risks.

(Reporting by Conor Humphries
Editing by Chris Reese)

Related Shares

More News
Today 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for pr...

Today 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood canc...

29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negoti...

29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while a...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.